Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.

Guardant Health (Nasdaq: GH) has expanded its testing portfolio by introducing a comprehensive immunohistochemistry (IHC) testing suite for solid tumors. The new tests detect specific proteins (biomarkers) in tissue samples to help oncologists identify tumor characteristics and match patients with targeted therapies. The IHC suite covers key biomarkers including HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1.This addition complements Guardant's existing Guardant360 Tissue multiomic tumor profiling test. Notably, the suite includes testing for c-MET, which is crucial for identifying patients eligible for the newly FDA-approved Emrelis™ treatment for c-MET-expressing non-squamous non-small cell lung cancer (NSCLC).

I-Mab completes enrollment for givastomig combination therapy study in gastric cancer, showing promising safety profile. Phase 1 results demonstrate 16.3% response rate in monotherapy.

ession of claudin 18.2 in gastric cancer was performed using the PubMed database. The following search expression was used: (“Stomach Neoplasms” [Mesh]) AND ((“claudin-18[TIAB]”) OR (“CLDN18[TIAB]”))....

This is the first randomised controlled trial of CAR T-cell therapy in solid tumours globally. Satri-cel treatment resulted in a significant improvement in progression-free survival, with a manageable...

New cancer tests at the Mater Hospital are offering fresh hope to patients with some of the most aggressive and hard-to-treat forms of the disease. Claudin-18 (CLDN18) and Folate Receptor-1 (FOLR-1) testing allows doctors to identify which patients are most likely to benefit from highly targeted, potentially life-extending immunotherapies, even when conventional treatments have failed. […]